IL264538B2 - A new use of n,n-bis-2-mercaptoethyl isophthalamide - Google Patents

A new use of n,n-bis-2-mercaptoethyl isophthalamide

Info

Publication number
IL264538B2
IL264538B2 IL264538A IL26453819A IL264538B2 IL 264538 B2 IL264538 B2 IL 264538B2 IL 264538 A IL264538 A IL 264538A IL 26453819 A IL26453819 A IL 26453819A IL 264538 B2 IL264538 B2 IL 264538B2
Authority
IL
Israel
Prior art keywords
bis
pharmaceutically
mercaptoethyl isophthalamide
nbmi
isophthalamide
Prior art date
Application number
IL264538A
Other languages
English (en)
Hebrew (he)
Other versions
IL264538B (en
IL264538A (enExample
Inventor
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Original Assignee
Emeramed Ltd
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Ltd, Boyd Eugene Haley, Ragnar Axel Theodor Klingberg filed Critical Emeramed Ltd
Publication of IL264538A publication Critical patent/IL264538A/en
Publication of IL264538B publication Critical patent/IL264538B/en
Publication of IL264538B2 publication Critical patent/IL264538B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL264538A 2016-08-05 2019-01-29 A new use of n,n-bis-2-mercaptoethyl isophthalamide IL264538B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201613535 2016-08-05
PCT/GB2017/052306 WO2018025049A1 (en) 2016-08-05 2017-08-04 New use of n,n-bis-2-mercaptoethyl isophthalamide

Publications (3)

Publication Number Publication Date
IL264538A IL264538A (enExample) 2019-03-31
IL264538B IL264538B (en) 2022-10-01
IL264538B2 true IL264538B2 (en) 2023-02-01

Family

ID=60202272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264538A IL264538B2 (en) 2016-08-05 2019-01-29 A new use of n,n-bis-2-mercaptoethyl isophthalamide

Country Status (31)

Country Link
US (2) US20190240173A1 (enExample)
EP (2) EP4029497A1 (enExample)
JP (1) JP6926192B2 (enExample)
KR (1) KR102538388B1 (enExample)
CN (1) CN109562179A (enExample)
AU (1) AU2017305661B2 (enExample)
BR (1) BR112019002130A2 (enExample)
CL (1) CL2019000229A1 (enExample)
CY (1) CY1125039T1 (enExample)
DK (1) DK3493849T3 (enExample)
EA (1) EA201990443A1 (enExample)
ES (1) ES2907838T3 (enExample)
HR (1) HRP20220252T1 (enExample)
HU (1) HUE057782T2 (enExample)
IL (1) IL264538B2 (enExample)
LT (1) LT3493849T (enExample)
MA (1) MA45855B1 (enExample)
MD (1) MD3493849T2 (enExample)
MX (1) MX387853B (enExample)
MY (1) MY199733A (enExample)
NZ (1) NZ750271A (enExample)
PH (1) PH12019500237A1 (enExample)
PL (1) PL3493849T3 (enExample)
PT (1) PT3493849T (enExample)
RS (1) RS62924B1 (enExample)
SG (1) SG11201900565RA (enExample)
SI (1) SI3493849T1 (enExample)
SM (1) SMT202200109T1 (enExample)
UA (1) UA125394C2 (enExample)
WO (1) WO2018025049A1 (enExample)
ZA (1) ZA201900594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227812A1 (en) * 2008-12-06 2010-09-09 Haley Boyd E Method of supplementing the diet and ameliorating oxidative stress

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
AU2010297933A1 (en) 2009-09-28 2012-04-19 University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227812A1 (en) * 2008-12-06 2010-09-09 Haley Boyd E Method of supplementing the diet and ameliorating oxidative stress

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KALSI S. S. ET AL.:, A REVIEW OF THE EVIDENCE CONCERNING HEPATIC GLUTATHIONE DEPLETION AND SUSCEPTIBILITY TO HEPATOTOXICITY AFTER PARACETAMOL OVERDOSE, 23 December 2011 (2011-12-23) *
KHAYYAT A. ET AL.:, CONTRIBUTION OF N-ACETYLCYSTEINEAMIDE AS A NEW THIOL-ANTIOXIDANT IN THE TREATMENT OF ACETAMINOPHEN TOXICITY, 1 October 2015 (2015-10-01) *
KISAOGLU A. ET AL.:, DAMAGE INDUCED BY PARACETAMOL COMPARED WITH N-ACETYLCYSTEINE, 12 July 2014 (2014-07-12) *

Also Published As

Publication number Publication date
MA45855B1 (fr) 2022-02-28
MA45855A (fr) 2021-03-17
EP4029497A1 (en) 2022-07-20
AU2017305661B2 (en) 2023-05-18
EA201990443A1 (ru) 2019-07-31
CY1125039T1 (el) 2023-03-24
EP3493849A1 (en) 2019-06-12
JP2019524782A (ja) 2019-09-05
PT3493849T (pt) 2022-02-23
ZA201900594B (en) 2019-08-28
RS62924B1 (sr) 2022-03-31
KR20190035724A (ko) 2019-04-03
CA3032858A1 (en) 2018-02-08
LT3493849T (lt) 2022-03-10
MX2019000978A (es) 2019-06-10
KR102538388B1 (ko) 2023-05-30
IL264538B (en) 2022-10-01
US20250325503A1 (en) 2025-10-23
PL3493849T3 (pl) 2022-03-28
US20190240173A1 (en) 2019-08-08
MD3493849T2 (ro) 2022-04-30
CL2019000229A1 (es) 2019-04-26
MX387853B (es) 2025-03-19
MY199733A (en) 2023-11-21
WO2018025049A1 (en) 2018-02-08
SMT202200109T1 (it) 2022-05-12
ES2907838T3 (es) 2022-04-26
HUE057782T2 (hu) 2022-06-28
AU2017305661A1 (en) 2019-02-14
BR112019002130A2 (pt) 2019-05-14
HRP20220252T1 (hr) 2022-04-29
JP6926192B2 (ja) 2021-08-25
EP3493849B1 (en) 2021-12-01
NZ750271A (en) 2025-07-25
UA125394C2 (uk) 2022-03-02
SG11201900565RA (en) 2019-02-27
SI3493849T1 (sl) 2022-04-29
PH12019500237A1 (en) 2019-10-28
CN109562179A (zh) 2019-04-02
IL264538A (enExample) 2019-03-31
DK3493849T3 (en) 2022-03-07

Similar Documents

Publication Publication Date Title
ZA201902053B (en) Pharmaceutical composition
WO2018004283A3 (ko) 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
EP3684334C0 (en) PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS MIXTURES OF PHARMACEUTICALLY ACCEPTABLE WATER-MISCIBLE SOLVENTS
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
MX387725B (es) Composición farmacéutica.
MX2020012989A (es) Agente terapeutico para la fibrosis.
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
MX2018006799A (es) Composicion farmaceutica.
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
WO2016130581A8 (en) Combination cancer therapy
AR111760A1 (es) Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
PH12018500817B1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
WO2020018053A3 (en) The tablet comprising dasatinib
JP2019524782A5 (enExample)
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
WO2020139238A3 (en) Pharmaceutical combinations comprising fingolimod and a spasmolytic
WO2019245512A3 (en) A combination comprising fingolimod and at least one anti-epileptic agent
HK40059961A (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
WO2019221684A3 (en) The bilayer tablet formulation of fesoterodine
HK40060762A (en) Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same